Rami Haddad, MD
Hematology & Oncology · Oak Lawn, ILNPI 1710072624
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.8%. Reporting peaked in 2021 at $10,021 and has fallen 52.1% since, to $4,801 in 2025.
Across 1,363 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Regeneron Healthcare Solutions, Inc.$3K
- Novartis$3K
- Pfizer$3K
- Amgen$3K
- Exelixis Inc.$2K
- plus $20K from 54 others
Across 452 payments — averaging $3093.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$664K
- Amgen$352K
- AstraZeneca$78K
- E.r. Squibb & Sons, L.L.C.$59K
- Radius Health, Inc.$57K
- Janssen Research & Development, LLC$54K
- plus $134K from 11 others
What the payments were for
- Consulting fees$14,38132%
- Speaking & faculty fees$3,1807%
- Food & beverage$23,25652%
- Education$2,4946%
- Other$1,0152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,326 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 93 | $1,479,818 |
| CalquenceAcalabrutinib Maleate | 52 | $764,561 |
| VenclextaVenetoclax | 55 | $702,280 |
| VonjoPacritinib Citrate | 17 | $431,158 |
| KisqaliRibociclib Succinate | 23 | $366,651 |
| IbrancePalbociclib | 19 | $312,775 |
| TagrissoOsimertinib Mesylate | 12 | $169,144 |
| EliquisApixaban | 204 | $150,259 |
| ErleadaApalutamide | 11 | $148,341 |
| XtandiEnzalutamide | 11 | $103,369 |
| Abiraterone Acetate | 11 | $62,816 |
| XareltoRivaroxaban | 64 | $41,533 |
| Letrozole | 150 | $2,549 |
| Anastrozole | 113 | $2,060 |
| Levothyroxine Sodium | 27 | $1,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $515 | $1,479,81893 claims |
| AstraZenecaCalquence, Tagrisso | $10,121 | $933,70564 claims |
| AbbVieVenclexta, Synthroid | $489 | $702,85267 claims |
| PfizerIbrance, Eliquis | $2,670 | $463,035223 claims |
| NovartisKisqali | $2,910 | $366,65123 claims |
| Johnson & JohnsonErleada, Xarelto | $1,375 | $189,87475 claims |
| Astellas Pharma US IncXtandi | $447 | $103,36911 claims |
| Lilly USA, LLCOlanzapine | $966 | $10115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Oak Lawn
- Amar HamadOak Lawn$121K
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.